Consumers Injury Help
Ozempic Lawsuit

Ozempic Gastroparesis Lawsuit

Patients who used Ozempic, Mounjaro, or Saxenda and suffered severe gastrointestinal injuries including gastroparesis, bowel obstruction, or ileus may be entitled to significant compensation. Get your free case review today.

Get A Free Case Review
MDL 3094 - Active Litigation

ATTENTION: OZEMPIC USERS

If you developed gastroparesis, bowel obstruction, or severe stomach problems after using Ozempic, you could be entitled to SIGNIFICANT compensation!

Consumers Injury Help offers a completely free case review and manages the entire process. Over 3,000 cases are consolidated in MDL 3094 before the Eastern District of Pennsylvania. Bellwether trials are expected in late 2026.

Find Out if You Qualify

SIGNIFICANT Compensation May Be Available

Did you use Ozempic, Mounjaro, Saxenda, or similar GLP-1 products?

What type of gastrointestinal injury did you experience?

Were you hospitalized for this condition?

Do you already have an attorney?

LARGE SETTLEMENT AMOUNT

COULD BE CLAIMED

How do we help YOU?

MDL 3094 consolidates over 3,191 Ozempic lawsuits in the Eastern District of Pennsylvania. Novo Nordisk failed to warn that semaglutide carries a 3.3× higher gastroparesis risk. The FDA updated warnings in 2023 and 2025 — but thousands were already harmed. Bellwether trials are expected late 2026.

How does filing a claim work?

  • 1. Fill out our simple form. Or call to make your claim immediately.
  • 2. Get a FREE case review from our expert partners.
  • 3. We fight on your behalf for the highest compensation possible.
  • 4. Claim your settlement!
  • Remember: you only pay if you get a settlement! Our service is totally RISK FREE.

Research shows semaglutide carries a 3.3× higher gastroparesis risk — and 19% of GLP-1 patients develop delayed gastric emptying.

Novo Nordisk did not adequately warn patients that Ozempic can cause stomach paralysis requiring hospitalization or feeding tube placement. The FDA added an ileus warning in September 2023 and updated the label in January 2025 — but thousands were harmed before these warnings were issued.

What Is the Ozempic Lawsuit About?

Ozempic (semaglutide) is a GLP-1 receptor agonist by Novo Nordisk used to treat Type 2 diabetes and, as Wegovy, for weight loss. Lawsuits allege Novo Nordisk failed to warn prescribers and patients that the drug can cause gastroparesis — stomach paralysis sometimes requiring hospitalization and feeding tube placement.

MDL 3094 is in the Eastern District of Pennsylvania under Judge Karen Spencer Marston. Over 3,191 cases were pending as of February 2026. No settlements have been reached.

Who Qualifies for the Ozempic Lawsuit?

You may qualify if you took Ozempic, Wegovy, Mounjaro, or another GLP-1 drug and developed a serious gastrointestinal condition, especially if you required hospitalization or surgery.

Did Ozempic or Wegovy cause your injury?

Get A Free Case Review

Health Conditions Linked to Ozempic

  • Gastroparesis — stomach paralysis, severe nausea and vomiting
  • Intestinal obstruction — blockage requiring hospitalization or surgery
  • Ileus — paralysis of the intestines
  • Pulmonary aspiration — food entering the lungs due to delayed gastric emptying
  • Acute kidney injury — from severe dehydration caused by vomiting
  • Deep vein thrombosis (DVT)

Ozempic Lawsuit Timeline

  • August 2023: First gastroparesis lawsuit filed (Bjorklund v. Novo Nordisk)
  • September 2023: FDA added ileus warning to label
  • February 2024: MDL 3094 formed with 55 initial cases
  • January 2025:FDA updated label — Ozempic "not recommended in patients with severe gastroparesis"
  • February 2026: 3,191 cases pending
  • Late 2026: Bellwether trials anticipated